Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCZ696 versus ramipril after acute myocardial infarction in high-risk patients
NL-OMON47687Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myocardial infarction (MI) and left ventricular systolic dysfunction (LVSD) comparing LCZ696 with Ramipril (2 arms). Primary endpoint: Time to first composite event of cardiovascular death, heart failure hospitalization, or outpatient heart failure. Started Feb 2017; status: active, not recruiting.
02
Drugs
sacubitril + valsartanramipril
03
Conditions
myocardial infarction (MI)left ventricular systolic dysfunction (LVSD)
Beyond the preview
Go deeper on NL-OMON47687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47687.